Scavestrogen sulfamates: Correlation between estrone sulfatase inhibiting and antioxidant effects

Canadian Journal of Physiology and Pharmacology

Volumn 76, Issue 2, 1998, Pages 99-109

  Römer, Wolfgang ^a   Oettel, Michael ^a   Schwarz, Sigfrid ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Estrogen 3 O sulfamates; Estrone sulfatase; Human placental microsomes; Iron redox chemistry; Lipid peroxidation; Phenylsulfatase; Radical scavenging effects

Indexed keywords

17ALPHA ESTRADIOL; 17BETA DIHYDROEQUILENIN SULFAMATE; ESTRADIOL; ESTROGEN; ESTRONE SULFATE; LIPID PEROXIDE; PHENYLSULFATASE; SCAVENGER; SCAVESTROGEN SULFAMATE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MALE; MICROSOME; NONHUMAN; PLACENTA; PRIORITY JOURNAL; RAT; SYNAPTOSOME;

EID: 0031802144     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y98-005     Document Type: Article

References (58)

1. Adams, M.R., Register, T.C., Golden, D.L., Wagner, J.D., and Williams, J.K. 1997. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vase. Biol. 17: 217-221.
2. Anderson, C., Freeman, J., Lucas, L.H., Farley, M., Dalhoumi, H., and Widlanski, T.S. 1997. Estrone sulfatase: probing structural requirements for substrate and inhibitor recognition. Biochemistry, 36: 2586-2594.
3. Aruoma, O.I. 1996. Characterization of drugs as antioxidant prophylactics. Free Radical Biol. Med. 20: 675-705.
4. Bhavnani, B.R. 1988. The saga of ring B unsaturated equine estrogens. Endocr. Rev. 9: 396-416.
5. Bradlow, H.L. 1982. A reassessment of the role of breast tumor aromatization. Cancer Res. 42: 3382s-3386s.
6. Braughler, J.M., Hall, E.D., Jacobsen, E.J., McCalIl, J.M., and Means, E.D. 1989. The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drug Future, 14: 141-152.
7. Buege, A., and Aust, S.D. 1978. Microsomal lipid peroxidation: Methods Enzymol. 52: 302-310.
8. Chetrite, G., Paris, J., Botella, J., and Pasqualini, J.R. 1996. Effect of nome-gestrel acetate on estrone-sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 58: 525-531.
9. Dibbelt, L., Li, P.-K., Pillai, R., and Knuppen, R. 1994. Inhibition of human placental sterylsulfatase by synthetic analogs of estrone sulfate. J. Steroid Biochem. Mol. Biol. 50: 261-266.
10. Ditkoff, E.C., Crary, W.G., Christo, M., and Lobo, R.A. 1991. Estrogen improves psychological function in asymptomatic post-menopausal women. Obstet. Gynecol. 78: 991-995.
11. Duncan, L.A., Purohit, A., Howarth, N.M., Potter, B.V.L., and Reed, M.J. 1993. Inhibition of estrone sulfatase activity by estrone-3-methylthiophosphonate: a potential therapeutic agent in breast cancer. Cancer Res. 53: 298-303.
12. Elger, W., Schwarz, S., Hedden, A., Reddersen, G., and Schneider, B. 1995. Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J. Steroid Biochem. Mol. Biol. 55: 395-403.
13. Evans, T.R., Rowlands, M.G., Jarman, M., and Coombes, R.C. 1991. Inhibition of estrone sulfatase enzyme in human placenta and human breast carcinoma. J. Steroid Biochem. Mol. Biol. 39: 493-499.
14. 2•. Free Radical Biol. Med. 15: 447-451.
15. Guetta, V., and Cannon III, R.O. 1996. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation, 93: 1928-1937.
16. Howarth, N.M., Purohit, A., Reed, M.J., and Potter, B.V.L. 1994. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 37: 219-221.
17. Howarth, N.M., Purohit, A., Reed, M.J., and Potter, B.V.L. 1997. Estrone sulfonates as inhibitors of estrone sulfatase. Steroids, 62: 346-350.
18. Huber, J., and Gruber, D. 1994. Hormone replacement therapy, endocrine monitoring and cyst fluid investigations in patients who have had a breast cyst. Endocrine-Related Cancer, 2: 57-61.
19. Komura, E., Takahashi, M., Morita, T., Tsuchiya, J., Arakawa, Y., Yamamoto, Y., and Niki, E. 1990. Inhibition of peroxidations of lipids and membranes by estrogens. J. Phys. Org. Chem. 3: 309-315.
20. Laihia, J.K., Jansen, C.T., and Ahotupa, M. 1993. Lucigenin and linoleate enhanced chemiluminescent assay for superoxide dismutase activity. Free Radical Biol. Med. 14: 457-461.
21. Li, P.K., Pillai, R., Young, B.L., Bender, W.H., Martino, D.M., and Lin, F.T. 1993. Synthesis and biochemical studies of estrone sulfatase inhibitors. Steroids, 58: 106-111.
22. Li, P.-K., Pillai, R., and Dibbelt, L. 1995. Estrone sulfate analogs as estrone sulfatase inhibitors. Steroids, 60: 299-306.
23. Marciniak, G., and Petty, M.A. 1996. Design and biological evaluation of new antioxidants for use in cerebrovascular disorders. Drugs Future, 21: 1037-1046.
24. Miller, D.M., Grover, T.A., Nayni, N., and Aust, S.A. 1993a. Xanthine oxidase- and iron-dependent lipid peroxidation. Arch. Biochem. Biophys. 301: 1-7.
25. Miller, N.J., Rice-Evans, C., Davies, M.J., Gopinathan, V., and Milner, A. 1993b. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin. Sc. 84: 407-412.
26. Mooradian, A.D. 1993. Antioxidant properties of steroids. J. Steroid Biochem. Mol. Biol. 45: 509-511.
27. Noel, C.T., Reed, M.J., Jacobs, H.S., and James, V.H.T. 1981. The plasma concentration of oestrone sulphate in postmenopausal women: lack of diurnal variation, effect of ovariectomy, age and weight. J. Steroid Biochem. 14: 1101-1105.
28. Pasqualini, J.R., Gelly, C., Nguygen, B.L., and Vella, C. 1989. Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. 34: 155-163.
29. Pasqualini, J.R., Chetrite, G., and Le Nestour, E. 1996. Control and expression of oestrone sulphatase activities in human breast cancer. J. Endocrinol. 150: S99-S105.
30. Purohit, A., Dauvois, S., Parker, M.G., Potter, B.V.L., Williams, G.J., and Reed, M.J. 1994a. The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells. J. Steroid Biochem. Mol. Biol. 50: 101-104.
31. Purohit, A., Howarth, N.M., Potter, B.V.L., and Reed, M.J. 1994b. Inhibition of steroid sulphatase activity by steroidal methylthiophosphonates: potential therapeutic agents in breast cancer. J. Steroid Biochem. Mol. Biol. 48: 523-527.
32. Purohit, A., Williams, G.J., Howarth, C.J., Potter, B.V.L., and Reed, M.J. 1995a. Inactivation of steroid sulphatase by an active site-directed inhibitor, oestrone-3-O-sulphamate. Biochemistry, 34: 11 508-11 514.
33. Purohit, A., Williams, G.J., Roberts, C.J., Potter, B.V.L., and Reed, M.J. 1995b. In vivo inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-O-sulphamate. Int. J. Cancer, 62: 106-111.
34. Reed, M.J., Purohit, A., Howarth, N.M., and Potter, B.V.L. 1994. Steroid sulphatase inhibitors: a new endocrine therapy. Drugs Future, 19: 673-676.
35. Reed, M.J., Purohit, A., Duncan, L.J., Singh, A., Roberts, C.J., Williams, G.J., and Potter, B.V.L. 1995. The role of cytokines and sulphatase inhibitors in regulating oestrogen synthesis in breast tumours. J. Steroid Biochem. Mol. Biol. 53: 413-420.
36. Reed, M.J., Purohit, A., Woo, L.W.L., and Potter, B.V.L. 1996. The development of steroid sulphatase inhibitors. Endocrine-Related Cancer, 3: 9-23.
37. Römer, W., Schwarz, S., Siemann, H.J., Droescher, P., Hirschelmann, R., Klinger, W., Heller, R., and Oettel, M. 1995a. Enhancement of the antioxidative activities of estradiol 17alpha. Proceedings of the 77th Annual Meeting, The Endocrine Society, U.S.A., June 14-17, 1995, Washington, D.C. p. 643. (Abstr.)
38. Römer, W., Hirschelmann, R., and Oettel, M. 1995b. Antioxidative, anti-arthritic as well as antileukemic activities of 17α-estradiol and derivatives. Proceedings of the Conference on Natural Antioxidants and Lipid Peroxidation in Atherosclerosis and Cancer. August 22-25, 1995, Helsinki, Finland, pp. PA-D18.
39. Römer, W., Oettel, M., and Schwarz, S. 1996. 17α-Estradiol 3-O-amidosulfonates: aryl-sulfatase sulfohydrolase inhibiting and radical scavenging effects. Gynecol. Endocrinol. 10(Suppl. 4): 156.
40. 8,9-dehydro derivatives of 17α-estradiol and 17β-estradiol. Steroids, 62: 304-310.
41. 9(11)-dehydro-17β-estradiol. Steroids, 62: 688-694.
42. Ruiz-Larrea, B., Leal, A., Martin, C., Martinez, R., and Lacort, M. 1995. Effects of estrogens on the redox chemistry of iron: a possible mechanism of the antioxidant action of estrogens. Steroids, 60: 780-783.
43. Sano, M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., Schneider, L.S., and Thal, L.J. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336: 1216-1222.
44. Santner, S.J., Feil, P.D., and Santen, R.J. 1984. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab. 59: 29-33.
45. Schwarz, S., and Elger, W. 1996. Estrogen sulfamates, a novel approach to oral contraception and hormone replacement therapy. Drugs Future, 21: 49-61.
46. Schwarz, S., Thieme, I., Richter, M., Undeutsch, B., Henkel, H., and Elger, W. 1996. Synthesis of estrogen sulfamates: compounds with a novel endocrinological profile. Steroids, 61: 710-717.
47. Selcer, K.W., and Li, P.K. 1995. Estrogenicity, antiestrogenicity and estrone sulfatase inhibition of estrone-3-amine and estrone-3-thiol. J. Steroid Biochem. Mol. Biol. 52: 281-286.
48. Sherwin, B.B. 1988. Hormones, mood, and cognitive functioning in post-menopausal women. Obstet. Gynecol. 87: 20S-26S.
49. Sherwin, B.B. 1996. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. Obstet. Gynecol. 14: 177-187.
50. Subbiah, M.T.R., Kessel, B., Agrawal, M., Rajan, R., Abplanalp, W., and Rymaszewski, Z. 1993. Antioxidant potential of specific estragons on lipid peroxidation. J. Clin. Endocrinol. Metabol. 77: 1095-1097.
51. Tang, M., Abplanalp, W., Ayres, S., and Subbiah, M.T.R. 1996. Superior and distinct antioxidant effects of selected estrogen metabolites on lipid peroxidation. Metabolism, 45: 411-414.
52. Theriault, R.L. 1996. Hormone replacement therapy and breast cancer: an overview. Br. J. Obstet. Gynaecol. 103(Suppl. 13): 87-91.
53. Wagner, J.D., Washburn, S.A., Zhang, L., Honoré, E.K., Williams, J.K., and Schwenke, C. 1995. A non-feminizing conjugated equine estrogen decreases arterial LDL degradation and improves vascular reactivity in male rhesus monkeys. Circulation, 92: 1-627. (Abstr.)
54. Washburn, S.A., Adams, M.R., Clarkson, T.B., and Adelman, S.J. 1993. A conjugated equine estrogen with differential effects on uterine weight and plasma cholesterol in the rat. Am. J. Obstet. Gynecol. 169: 251-256.
55. Washburn, S.A., Honoré, E.K., Cline, J.M., Helman, M., Wagner, J.D., Adams, M.R., Adelman, S.J., and Clarkson, T.B. 1996. Effects of 17α-dihydroequilenin sulfate on atherosclerotic male and female rhesus monkeys. Am. J. Obstet. Gynecol. 175: 341-351.
56. Wilcox, J.G., Hodis, H.N., Sevanian, A., Stanczyk, F.Z., and Lobo, R.A. 1995. The biological effects of individual estrogen components in conjugated equine estrogens (CEE) and their possible modulation of insulin resistance and oxidation of LDL. J. Soc. Gynecol. Invest. 2: 153.
57. Wilcox, J.G., Hwang, J., Hodis, H.N., Sevanian, A., Stanczyk, F.Z., and Lobo, R.A. 1997. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil. Steril. 67: 57-62.
58. Wiseman, H., and Reilly, J.O. 1997. Molecular action of oestrogens in the prevention of cardiovascular disease. Oestrogens as antioxidant cardioprotectants. Biochem. Soc. Trans. 25: 54-59.